Sucraid (Sacrosidase Oral Solution)
برای این دارو، اطلاعات عمومی (فارسی) یافت نشد . برای افزودن اطلاعات فارسی به این دارو کلیک نمایید.
Sucraid (Sacrosidase Oral Solution)

Sucraid®
(sacrosidase) Oral Solution

DRUG DESCRIPTION

Sucraid® (sacrosidase) oral solution is an enzyme replacement therapy for the treatment of the genetically determined sucrase deficiency, which is part of congenital sucrase-isomaltase deficiency (CSID).

Sucraid® (sacrosidase oral solution) is a pale yellow, clear solution with a pleasant sweet taste. Each milliliter (mL) of Sucraid (sacrosidase oral solution) ® contains 8,500 International Units (I.U) of the enzyme sacrosidase, the active ingredient. The chemical name of this enzyme is ß,D-fructofuranoside fructohydrolase. The enzyme is derived from baker's yeast (saccharomyces cerevisiae). It has been reported that the primary amino acid structure of this protein consists of 513 amino acids with an apparent molecular weight of 100,000 g/mole for the glycosolated monomer (range 66,000-116,000 g/mole). Reports also suggest that the protein exists in solution as a monomer, dimmer, tetramer, and octomer ranging from 100,000 g/mole to 800,000 g/mole. It has an isoelectric point of 4 (pl=4.093).

Sucraid® (sacrosidase oral solution) also contains 50% glycerol in an aqueous solution. Glycerol (glycerin) in the amount consumed in the recommended doses of Sucraid® (sacrosidase oral solution) has no expected toxicity.
This enzyme preparation is fully soluble with water, milk, and infant formula

(DO NOT HEAT SOLUTIONS CONTAINING Sucraid® (sacrosidase oral solution) ). Do not put Sucraid (sacrosidase oral solution) ® in warm or hot liquids.

What are the possible side effects of sacrosidase (Sucraid)?

Stop using this medication and get emergency medical help if you have any of these signs of an allergic reaction: hives; wheezing, difficulty breathing; swelling of your face, lips, tongue, or throat.

Less serious side effects may include:

  • stomach pain;
  • nausea, vomiting;
  • diarrhea, constipation;
  • sleep problems (insomnia);
  • headache;
  • nervous feeling; or
  • increased thirst and dry, hot skin.

Some of these may be symptoms of your condition and not actual side effects of sacrosidase.

This is not a...

Read All Potential Side Effects and See Pictures of Sucraid »

Last reviewed on RxList: 2/13/2009
This monograph has been modified to include the generic and brand name in many instances.

INDICATIONS

Sucraid® (sacrosidase) oral solution is indicated as oral replacement therapy of the genetically determined sucrase deficiency, which is part of congenital sucrase-isomaltase deficiency. (CSID)

DOSAGE AND ADMINISTRATION

The recommended dosage is 1 or 2 mL (8,500 to 17,000 I.U.) or 1 or 2 full measuring scoops (each full measuring scoop equals 1mL; 22 drops from the Sucraid® (sacrosidase oral solution) container tip equals 1mL) taken orally with each meal or snack diluted with 2 to 4 ounces of water, milk or infant formula. The beverage or infant formula should be served cold or at room temperature. The beverage or infant formula should not be warmed or heated before or after addition of Sucraid® (sacrosidase oral solution) because heating is likely to decrease potency. Sucraid® (sacrosidase oral solution) should not be reconstituted or consumed with fruit juice since its acidity may reduce the enzyme activity. It is recommended that approximately half of the dosage be taken at the beginning of the meal or snack and the remainder be taken during the meal or snack. The recommended dosage is as follows: 1 mL (8,500 I.U) (one full measuring scoop or 22 drops) per meal or snack for patients up to 15kg in body weight. 2mL (17,000 I.U) (two full measuring scoops or 44 drops) per meal or snack for patients over 15 kg in body weight. Dosage may be measured with the 1 mL measuring scoop (provided) or by drop count method (1mL equals 22 drops from the Sucraid® (sacrosidase oral solution) container tip).

HOW SUPPLIED

Sucraid® (sacrosidase oral solution) is available in 118 mL (4 fluid ounces) translucent plastic bottles, packaged two bottles per box. Each mL of solution contains 8,500 International Units (I.U.) of sacrosidase. Each bottle is supplied with a plastic puncturing cap that is used to open the sealed bottle at first use and to reseal it after each use. In addition, a 1mL measuring scoop is provided with each bottle. A full measuring scoop is 1mL. Store in a refrigerator at 2°-8° C (36°-46°F). Discard four weeks after first opening due to the potential for bacterial growth. Protect from heat and light.

To order, or for any questions call 1-800-424-9002. NDC# 67871-011-04. Manufactured for QOL Medial, LLC. , Kirkland, WA 98033, USA. FDA rev date: 11/20/2008

Last reviewed on RxList: 2/13/2009
This monograph has been modified to include the generic and brand name in many instances.

SIDE EFFECTS

Adverse experiences with Sucraid® (sacrosidase oral solution) in clinical trials were generally minor and were frequently associated with the underlying disease. In clinical studies of up to 54 months duration, physicians treated a total of 52 patients with Sucraid® (sacrosidase oral solution) . The adverse experiences and respective number of patients reporting each event (in parenthesis) were as follows: abdominal pain (4), vomiting (3), nausea (2), diarrhea (2), constipation (2), insomnia (1) headache (1) nervousness (1) and dehydration (1). Note: diarrhea and abdominal pain can be a part of the clinical presentation of the genetically determined sucrase deficiency, which is part of congenital sucrase-isomaltase deficiency (CSID). One asthmatic child experienced a serious hypersensitivity reaction (wheezing) probably related to sacrosidase (see WARNINGS). The event resulted in withdrawal of the patient from the trial but resolved with no sequelae.

Read the Sucraid (sacrosidase oral solution) Side Effects Center for a complete guide to possible side effects »

DRUG INTERACTIONS

Neither drug-drug nor drug-food interactions are expected or have been reported with the use of Sucraid® (sacrosidase oral solution) . However, Sucraid® (sacrosidase oral solution) should not be reconstituted or consumed with fruit juice, since its acidity may reduce the enzyme activity.

Last reviewed on RxList: 2/13/2009
This monograph has been modified to include the generic and brand name in many instances.

WARNINGS

Severe wheezing, 90 minutes after a second dose of sacrosidase, necessitated admission into the ICU for a 4-year old boy. The wheezing was probably caused by sacrosidase. He had asthma and was being treated with steroids. A skin test for sacrosidase was positive. Other serious events have not been linked to Sucraid® (sacrosidase oral solution) .

PRECAUTIONS

Care should be taken to administer initial doses of Sucraid® (sacrosidase oral solution) near (within a few minutes' travel) a facility where acute hypersensitivity reactions can be adequately treated. Alternatively, the patient may be tested for hypersensitivity to Sucraid® (sacrosidase oral solution) through skin abrasion testing. Should symptoms of hypersensitivity appear, discontinue medication and initiate symptomatic and supportive therapy. Skin testing as a rechallenge has been used to verify hypersensitivity in one asthmatic child who displayed wheezing after oral sacrosidase.

General

Although Sucraid® (sacrosidase oral solution) provides replacement therapy for the deficient sucrase, it does not provide specific replacement therapy for the deficient isomaltase. Therefore, restricting starch in the diet may still be necessary to reduce symptoms as much as possible. The need for dietary starch restriction for patients using Sucraid® (sacrosidase oral solution) should be evaluated in each patient. It may sometimes be clinically inappropriate, difficult or inconvenient to perform a small bowel biopsy or breath hydrogen test to make a definitive diagnosis of CSID. If the diagnosis is in doubt, it may be warranted to conduct a short therapeutic trial (e.g. one week) with Sucraid® (sacrosidase oral solution) to assess response in a patient suspected of sucrase deficiency.

The effects of SUCRAID (sacrosidase oral solution) have not been evaluated in patients with secondary (acquired) disaccharidase deficiencies.

Use in Diabetics

The use of Sucraid® (sacrosidase oral solution) will enable the products of sucrose hydrolysis- glucose and fructose to be absorbed. This fact must be carefully considered in planning the diet of diabetic CSID patients using Sucraid® (sacrosidase oral solution) .

Laboratory Tests

The definitive test for diagnosis of CSID is the measurement of intestinal disaccharidases following small bowel biopsy. Other tests used alone may be inaccurate: for example, the breath hydrogen test (high incidence of false-negatives) or oral sucrose tolerance test (high incidence of false positives). Differential urinary disaccharide testing has been reported to show good agreement with small intestinal biopsy for diagnosis of CSID.

Carcinogenesis, Mutagenesis, Impirment Of Fertility

Long-term studies in animals with SUCRAID (sacrosidase oral solution) have not been performed to evaluate the carcinogenic potential. Studies to evaluate the effect of Sucraid® (sacrosidase oral solution) on fertility or its mutogenic potential have not been performed.

Pregnancy

Teratogenic effects. Pregnancy Category C. Animal reproduction studies have not been conducted with Sucraid® (sacrosidase oral solution) . Sucraid® (sacrosidase oral solution) is not expected to cause fetal harm when administered to a pregnant woman or to affect reproductive capacity. Sucraid® (sacrosidase oral solution) should be given to a pregnant woman only if clearly needed.

Nursing Mothers

The Sucraid® (sacrosidase oral solution) enzyme is broken down in the stomach and intestines and the component amino acids and peptides are then absorbed as nutrients.

Pediatric Use

Sucraid® (sacrosidase oral solution) has been used in patients as young as 5 months of age. Evidence in one controlled trial in primarily pediatric patients shows that Sucraid® (sacrosidase oral solution) is safe and effective for the treatment of the genetically acquired sucrase deficiency, which is part of CSID.

Last reviewed on RxList: 2/13/2009
This monograph has been modified to include the generic and brand name in many instances.

OVERDOSE

Over dosage with Sucraid® (sacrosidase oral solution) has not been reported.

CONTRAINDICATIONS

Patients known to be hypersensitive to yeast, yeast products, or glycerin (glycerol).

Last reviewed on RxList: 2/13/2009
This monograph has been modified to include the generic and brand name in many instances.

CLINICAL PHARMACOLOGY

Congenital sucrase-isomaltase deficiency (CSID) is a chronic, autosomal recessive, inherited, phenotypically heterogeneous disease with very variable enzyme activity. CSID is usually characterized by a complete or almost complete lack of endogenous sucrase activity, a very marked reduction in isomaltase activity, a moderate decrease in maltase activity and normal lactase levels. Sucrase is naturally produced in the brush border of the small intestine, primarily the distal duodenum and jejunum. Sucrase hydrolyzes the disaccharide sucrose into its component monosaccharides, glucose and fructose. Isomaltase breaks down disaccharides from starch into simple sugars.

Sucraid® (sacrosidase oral solution) does not contain isomaltase. In the absence of endogenous human sucrase, as in CSID, sucrose is not metabolized. Unhydrolyzed sucrose and starch are not absorbed from the intestine and their presence in the intestinal lumen may lead to osmotic retention of water. This may result in loose stools. Unabsorbed sucrose in the colon is fermented by bacterial flora to produce increased amounts of hydrogen, methane and water. As a consequence, excessive gas, bloating, abdominal cramps, nausea and vomiting may occur. Chronic malabsorption of disaccharides may result in malnutrition.

Undiagnosed/untreated CSID patients often fail to thrive and fall behind in their expected growth and development curves. Previously, the treatment of CSID has required the continual use of a strict sucrose-free diet.

CSID is often difficult to diagnose. Approximately 4% to 10% of pediatric patients with chronic diarrhea of unknown origin have CSID.

Measurement of expired breath hydrogen under controlled conditions following a sucrose challenge ( a measurement of excess hydrogen excreted in exhalation) in CSID patients has shown levels as great as 6 times that in normal subjects.

A generally accepted clinical definition of CSID is that of a condition characterized by the following: stool pH <6, an increase in breath hydrogen of > 10ppm when challenged with sucrose after fasting and a negative lactose breath test.

However, because of the difficulties in diagnosing CSID, it may be warranted to conduct a short therapeutic trial (e.g. one week) to assess response in patients suspected of having CSID.

Clinical Studies

A two-phase (dose response preceded by a breath hydrogen phase) double-blind, multi-site, crossover trial was conducted in 28 patients (aged 4 months to 11.5 years) with confirmed CSID. During the dose response phase the patients were challenged with an ordinary sucrose containing diet while receiving each of four doses of sacrosidase: full strength (9000 I.U./mL) and three dilutions 1:10 (900 I.U./mL), 1:100 (90 I.U./mL) and 1:1000 (9I.U/mL) in random order for a period of 10 days. Patients who weighed no more than 15kg received 1mL per meal; those weighing more than 15kg received 2mL per meal. The dose did not vary with age or sucrose intake. A dose-response relationship was shown between the two higher and the two lower doses. The two higher doses of sacrosidase were associated with significantly fewer total stools and higher proportions of patients having lower total symptom scores, the primary efficacy end-points. In addition, higher doses of sacrosidase were associated with a significantly greater number of hard and formed stools as well as with fewer watery and soft stools, the secondary efficacy end-points. Analysis of the overall symptomatic response as a function of age indicated that in CSID patients up to 3 years of age, 86% became asymptomatic. In patients over 3 years of age 77% became asymptomatic. Thus, the therapeutic response did not differ significantly according to age. A second study of similar design and execution as the first used 4 different dilutions of sacrosidase 1:100 (90 I.U./mL) 1:1000 (9 I.U./mL) 1:10,000 (0.9 I.U./ml) 1:100,000 (0.09I.U/mL). There were inconsistent results with regards to the primary efficacy parameters. In both trials however, patients showed a marked decrease in breath hydrogen output when they received sacrosidase in comparison to placebo.

Last reviewed on RxList: 2/13/2009
This monograph has been modified to include the generic and brand name in many instances.

PATIENT INFORMATION

See Patient Package Insert. Patients should be instructed to discard bottles of Sucraid® (sacrosidase oral solution) 4 weeks after opening due to the potential for bacterial growth. For the same reason, patients should be advised to rinse the measuring scoop with water after each use. Sucraid® (sacrosidase oral solution) is fully soluble with water, milk and infant formula, but it is important to note that this product is sensitive to heat. Sucraid® (sacrosidase oral solution) should not be reconstituted or consumed with fruit juice, since its acidity may reduce the enzyme activity.

Last reviewed on RxList: 2/13/2009
This monograph has been modified to include the generic and brand name in many instances.

>

PATIENT INFORMATION

See Patient Package Insert. Patients should be instructed to discard bottles of Sucraid® (sacrosidase oral solution) 4 weeks after opening due to the potential for bacterial growth. For the same reason, patients should be advised to rinse the measuring scoop with water after each use. Sucraid® (sacrosidase oral solution) is fully soluble with water, milk and infant formula, but it is important to note that this product is sensitive to heat. Sucraid® (sacrosidase oral solution) should not be reconstituted or consumed with fruit juice, since its acidity may reduce the enzyme activity.

Last reviewed on RxList: 2/13/2009
This monograph has been modified to include the generic and brand name in many instances.

Sucraid®
(sacrosidase) Oral Solution

DRUG DESCRIPTION

Sucraid® (sacrosidase) oral solution is an enzyme replacement therapy for the treatment of the genetically determined sucrase deficiency, which is part of congenital sucrase-isomaltase deficiency (CSID).

Sucraid® (sacrosidase oral solution) is a pale yellow, clear solution with a pleasant sweet taste. Each milliliter (mL) of Sucraid (sacrosidase oral solution) ® contains 8,500 International Units (I.U) of the enzyme sacrosidase, the active ingredient. The chemical name of this enzyme is ß,D-fructofuranoside fructohydrolase. The enzyme is derived from baker's yeast (saccharomyces cerevisiae). It has been reported that the primary amino acid structure of this protein consists of 513 amino acids with an apparent molecular weight of 100,000 g/mole for the glycosolated monomer (range 66,000-116,000 g/mole). Reports also suggest that the protein exists in solution as a monomer, dimmer, tetramer, and octomer ranging from 100,000 g/mole to 800,000 g/mole. It has an isoelectric point of 4 (pl=4.093).

Sucraid® (sacrosidase oral solution) also contains 50% glycerol in an aqueous solution. Glycerol (glycerin) in the amount consumed in the recommended doses of Sucraid® (sacrosidase oral solution) has no expected toxicity.
This enzyme preparation is fully soluble with water, milk, and infant formula

(DO NOT HEAT SOLUTIONS CONTAINING Sucraid® (sacrosidase oral solution) ). Do not put Sucraid (sacrosidase oral solution) ® in warm or hot liquids.

Last reviewed on RxList: 2/13/2009
This monograph has been modified to include the generic and brand name in many instances.

Sucraid®
(sacrosidase) Oral Solution

DRUG DESCRIPTION

Sucraid® (sacrosidase) oral solution is an enzyme replacement therapy for the treatment of the genetically determined sucrase deficiency, which is part of congenital sucrase-isomaltase deficiency (CSID).

Sucraid® (sacrosidase oral solution) is a pale yellow, clear solution with a pleasant sweet taste. Each milliliter (mL) of Sucraid (sacrosidase oral solution) ® contains 8,500 International Units (I.U) of the enzyme sacrosidase, the active ingredient. The chemical name of this enzyme is ß,D-fructofuranoside fructohydrolase. The enzyme is derived from baker's yeast (saccharomyces cerevisiae). It has been reported that the primary amino acid structure of this protein consists of 513 amino acids with an apparent molecular weight of 100,000 g/mole for the glycosolated monomer (range 66,000-116,000 g/mole). Reports also suggest that the protein exists in solution as a monomer, dimmer, tetramer, and octomer ranging from 100,000 g/mole to 800,000 g/mole. It has an isoelectric point of 4 (pl=4.093).

Sucraid® (sacrosidase oral solution) also contains 50% glycerol in an aqueous solution. Glycerol (glycerin) in the amount consumed in the recommended doses of Sucraid® (sacrosidase oral solution) has no expected toxicity.
This enzyme preparation is fully soluble with water, milk, and infant formula

(DO NOT HEAT SOLUTIONS CONTAINING Sucraid® (sacrosidase oral solution) ). Do not put Sucraid (sacrosidase oral solution) ® in warm or hot liquids.

Last reviewed on RxList: 2/13/2009
This monograph has been modified to include the generic and brand name in many instances.

Sucraid®
(sacrosidase) Oral Solution

DRUG DESCRIPTION

Sucraid® (sacrosidase) oral solution is an enzyme replacement therapy for the treatment of the genetically determined sucrase deficiency, which is part of congenital sucrase-isomaltase deficiency (CSID).

Sucraid® (sacrosidase oral solution) is a pale yellow, clear solution with a pleasant sweet taste. Each milliliter (mL) of Sucraid (sacrosidase oral solution) ® contains 8,500 International Units (I.U) of the enzyme sacrosidase, the active ingredient. The chemical name of this enzyme is ß,D-fructofuranoside fructohydrolase. The enzyme is derived from baker's yeast (saccharomyces cerevisiae). It has been reported that the primary amino acid structure of this protein consists of 513 amino acids with an apparent molecular weight of 100,000 g/mole for the glycosolated monomer (range 66,000-116,000 g/mole). Reports also suggest that the protein exists in solution as a monomer, dimmer, tetramer, and octomer ranging from 100,000 g/mole to 800,000 g/mole. It has an isoelectric point of 4 (pl=4.093).

Sucraid® (sacrosidase oral solution) also contains 50% glycerol in an aqueous solution. Glycerol (glycerin) in the amount consumed in the recommended doses of Sucraid® (sacrosidase oral solution) has no expected toxicity.
This enzyme preparation is fully soluble with water, milk, and infant formula

(DO NOT HEAT SOLUTIONS CONTAINING Sucraid® (sacrosidase oral solution) ). Do not put Sucraid (sacrosidase oral solution) ® in warm or hot liquids.

Last reviewed on RxList: 2/13/2009
This monograph has been modified to include the generic and brand name in many instances.

Sucraid Patient Information Including Side Effects

Brand Names: Sucraid

Generic Name: sacrosidase (Pronunciation: sak ROE si dase)

What is sacrosidase (Sucraid)?

Sacrosidase is a yeast-based enzyme that replaces an enzyme called sucrase which is normally produced in the body. Sucrase helps the body breakdown and process certain sugars during digestion.

In people who lack the sucrase enzyme, sugar can pass into the intestines where it can interact with bacteria. This can cause bloating, gas, stomach pain, nausea, and vomiting.

Sacrosidase is used to treat sucrase deficiency that occurs in people with congenital sucrase-isomaltase deficiency (CSID).

CSID is a genetic enzyme deficiency and sacrosidase will not cure this condition.

Sacrosidase may also be used for purposes not listed in this medication guide.

What are the possible side effects of sacrosidase (Sucraid)?

Stop using this medication and get emergency medical help if you have any of these signs of an allergic reaction: hives; wheezing, difficulty breathing; swelling of your face, lips, tongue, or throat.

Less serious side effects may include:

  • stomach pain;
  • nausea, vomiting;
  • diarrhea, constipation;
  • sleep problems (insomnia);
  • headache;
  • nervous feeling; or
  • increased thirst and dry, hot skin.

Some of these may be symptoms of your condition and not actual side effects of sacrosidase.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Read the Sucraid (sacrosidase oral solution) Side Effects Center for a complete guide to possible side effects »

What is the most important information I should know about sacrosidase (Sucraid)?

Sacrosidase is used to treat sucrase deficiency that occurs in people with congenital sucrase-isomaltase deficiency (CSID). CSID is a genetic enzyme deficiency and sacrosidase will not cure this condition.

You should not use this medication if you are allergic to yeast, yeast products, glycerin (glycerol), or papain (Accuzyme, Ethezyme, Gladase, Kovia, and others).

Before using sacrosidase, tell your doctor if you have diabetes. Sacrosidase changes the way your body absorbs sugar and your glucose levels may change. Your doctor will tell you if any of your medication doses need to be changed.

This medication sometimes causes an allergic reaction. Before you start the medication, your doctor may recommend a sacrosidase skin test to make sure you are not allergic to the medication.

Sacrosidase is usually taken with each meal or snack. It is best to take one half of the dose when you start eating and take the other half during your meal or snack.

Measure your dose using the scoop provided with this medication.

Sacrosidase liquid should be mixed with 2 to 4 ounces of water, milk, or baby formula that is no hotter than room temperature. Do not mix with warm or hot liquids or the medication will not be as effective.

Do not mix sacrosidase with fruit juice or drink fruit juice when taking the medication.

You may need to avoid eating a lot of starch (found mainly in rice, potatoes, corn, pasta, and bread). Follow your doctor's instructions about any special diet while you are taking sacrosidase.

Side Effects Centers

Sucraid Patient Information including How Should I Take

What should I discuss with my health care provider before taking sacrosidase (Sucraid)?

You should not use this medication if you are allergic to yeast, yeast products, glycerin (glycerol), or papain (Accuzyme, Ethezyme, Gladase, Kovia, and others).

Before using sacrosidase, tell your doctor if you have diabetes. Sacrosidase changes the way your body absorbs sugar and your glucose levels may change. Your doctor will tell you if any of your medication doses need to be changed.

FDA pregnancy category C. This medication may be harmful to an unborn baby. Tell your doctor if you are pregnant or plan to become pregnant during treatment.

Tell your doctor if you are breast-feeding a baby while taking sacrosidase.

How should I take sacrosidase (Sucraid)?

Take this medication exactly as prescribed by your doctor. Do not take it in larger amounts or for longer than recommended. Follow the directions on your prescription label.

Sacrosidase is usually taken with each meal or snack. It is best to take one half of the dose when you start eating and take the other half during your meal or snack.

Measure your dose using the scoop provided with sacrosidase. Rinse the scoop after each use and allow it to dry thoroughly.

Sacrosidase liquid should be mixed with 2 to 4 ounces of water, milk, or baby formula that is no hotter than room temperature. Do not mix with warm or hot liquids or the medication will not be as effective.

Do not mix sacrosidase with fruit juice or drink fruit juice when taking the medication.

This medication sometimes causes an allergic reaction. Before you start the medication, your doctor may recommend a sacrosidase skin test to make sure you are not allergic to the medication.

Your doctor may instruct you to take your first dose of sacrosidase in a place where you have access to emergency medical care. A severe allergic reaction could occur that may require immediate care.

Store this medication in the refrigerator, protected from light. Do not freeze. Recap the bottle after each use.

When you first open a bottle of sacrosidase, write the date on the label. Throw away any unused sacrosidase 4 weeks after first opening the bottle.

Side Effects Centers

Sucraid Patient Information including If I Miss a Dose

What happens if I miss a dose (Sucraid)?

Take the missed dose as soon as you remember. If it is almost time for your next dose, wait until then to take the medicine and skip the missed dose. Do not take extra medicine to make up the missed dose.

What happens if I overdose (Sucraid)?

An overdose of sacrosidase is not likely to produce any symptoms.

What should I avoid while taking sacrosidase (Sucraid)?

You may need to avoid eating a lot of starch (found mainly in rice, potatoes, corn, pasta, and bread). Follow your doctor's instructions about any special diet while you are taking sacrosidase.

Follow your doctor's instructions about any other restrictions on food or beverages while you are using sacrosidase.

What other drugs will affect sacrosidase (Sucraid)?

There may be other drugs that can interact with sacrosidase. Tell your doctor about all your prescription and over-the-counter medications, vitamins, minerals, herbal products, and drugs prescribed by other doctors. Do not start a new medication without telling your doctor.

Where can I get more information?

Your pharmacist can provide more information about sacrosidase.


Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use this medication only for the indication prescribed.

Every effort has been made to ensure that the information provided by Cerner Multum, Inc. ('Multum') is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Multum information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Multum does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Multum's drug information does not endorse drugs, diagnose patients or recommend therapy. Multum's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Multum does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Copyright 1996-2012 Cerner Multum, Inc. Version: 1.05. Revision date: 12/15/2010.

Your use of the content provided in this service indicates that you have read,understood and agree to the End-User License Agreement,which can be accessed by clicking on this link.

Healthwise

Side Effects Centers

توزیع کنندگان این دارو
شرکت های تولید کننده یا وارد کننده دارو

دارونـــما
نوآوری برای سلامت

طراحی و اجرا M.Ramezani
ارتباط با ما Info@darunama.com